The combined use of autophagy inhibitors 3-Methyladenine (3-MA) and YC-1 (an inhibitor of HIF-1α), attenuated HMGB1 release in cancer cells, indicating a potential underlying mechanism regulating extracellular levels of HMGB1 and autophagy in OSCC cells [29]. Here, HMGB1 is linked to cancer.